Clinical Characteristics, Risk Factors, and Outcomes of Patients with Polymicrobial Klebsiella pneumoniae Bloodstream Infections
Table 4
Antimicrobial resistance of Klebsiella pneumoniae and antimicrobial therapy in patients with monomicrobial and polymicrobial K. pneumoniae bloodstream infection.
Bacteriology
Total ()
Monomicrobial ()
Polymicrobial ()
value
Antimicrobial resistance
Cefoxitin (650 vs. 109)
514 (67.2%)
432 (66.5%)
82 (75.2%)
0.070
Ceftazidime (601 vs. 94)
483 (69.5%)
411 (68.4%)
72 (76.6%)
0.108
Ceftriaxone (659 vs. 112)
552 (71.6%)
460 (69.8%)
92 (82.1%)
0.007
Cefepime (704 vs. 114)
531 (64.9%)
448 (63.6%)
83 (72.8%)
0.057
Amoxicillin-clavulanic acid (653 vs. 112)
541 (70.7%)
448 (68.6%)
93 (89.0%)
0.002
Piperacillin-tazobactam (704 vs. 114)
551 (67.4%)
463 (65.8%)
88 (77.2%)
0.016
Cefoperazone-sulbactam (654 vs. 103)
515 (68.0%)
436 (66.7%)
79 (76.7%)
0.042
Amikacin (704 vs. 114)
357 (43.6%)
303 (43.0%)
54 (47.4%)
0.387
Ciprofloxacin (704 vs. 114)
515 (63.0%)
438 (62.2%)
77 (67.5%)
0.274
Levofloxacin (704 vs. 114)
498 (60.9%)
423 (60.1%)
75 (65.8%)
0.247
Carbapenems (704 vs. 114)
551 (67.4%)
462 (65.6%)
89 (78.1%)
0.009
Tigecycline (605 vs. 94)
184 (26.3%)
158 (26.1%)
26 (27.7%)
0.752
Colistin (247 vs. 37)
5 (1.8%)
3 (1.2%)
2 (5.4%)
0.128
Appropriate empirical antimicrobial therapy, (%)
387 (47.3%)
341 (48.4%)
46 (40.4%)
0.109
The figures in parentheses were the total numbers of K. pneumoniae used for antimicrobial susceptibility testing in both groups.
